Clinical Takeaway
Children born to mothers who used cannabis during pregnancy showed a modestly elevated risk of autism spectrum disorder and a smaller increased risk of ADHD based on pooled data from 13 observational studies. These associations are statistically meaningful but modest in absolute terms, and observational designs cannot establish causation. Current evidence supports advising pregnant patients to avoid cannabis use given its potential to affect fetal brain development through cannabinoid receptors.
#14 Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.
Citation: Andrade Chittaranjan. Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.. The Journal of clinical psychiatry. 2024. PMID: 39724097.
Design: 6 Journal: 0 N: 2 Recency: 1 Pop: 3 Human: 1 Risk: -2
This meta-analysis provides quantified evidence that prenatal cannabis exposure confers a measurable increased risk for ASD (RR 1.30) and ADHD in offspring, addressing a critical gap given that up to 10% of pregnant women use cannabis and cannabinoid receptors are present in the developing fetal brain. These findings establish sufficient signal to inform clinical counseling protocols and public health guidelines regarding cannabis use during pregnancy, particularly as legalization increases population-level exposure. The effect sizes, while modest, translate to meaningful clinical burden at the population level and warrant prospective studies to clarify causality and identify vulnerable subgroups.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Retrospective design — selection and information bias risk
Abstract: Up to 10% of women may use cannabis during pregnancy; this is of concern because constituents of cannabis cross the placental barrier and potentially influence neurodevelopment by acting on cannabinoid receptors in the developing fetal brain. In this context, a recent meta analysis of 13 observational studies found that gestational exposure to cannabis was associated with a small increase in the risk of autism spectrum disorder (ASD; relative risk [RR], 1.30) and with an even smaller increase in the risk of attention deficit/hyperactivity disorder (ADHD; RR, 1.13); the latter finding was probably supported by publication bias. In this meta-analysis, 4 studies provided information on ASD (pooled N = 178,565) and 10 on ADHD (pooled N = 203,783). In a large (n = 222,534) retrospectively ascertained cohort study published after the meta-analysis, cannabis use disorder (CUD) recorded before pregnancy, during pregnancy, and during pregnancy plus the year after delivery were associated with closely similar increased risks of ASD (RRs, 3.02-3.21). The risks were smaller in smokers (RRs, 1.74-1.87) than in nonsmokers (RRs, 4.55-4.83) but differed little between male (RRs, 3.01-3.06) and female (RRs, 2.71-2.85) offspring. Although the cohort study had many strengths, its limitations permitted only the conclusion that peri-pregnancy exposure to CUD is associated with a large increase in the risk of ASD in offspring; it remained possible that much of the risk was driven by genetic, environmental, or behavioral variables. The field is nascent; the total number of cannabis exposed pregnancies (with ASD and ADHD as the outcomes) in world literature is small. However, cannabis use during pregnancy is, at the very least, a clear marker for adverse neurodevelopmental outcomes, besides the adverse maternal, fetal, and neonatal outcomes identified in other studies. Healthcare providers who manage women who use cannabis during pregnancy need to be aware of these adverse outcomes.
🧠 While this meta-analysis suggests a modest association between prenatal cannabis exposure and increased risk of autism spectrum disorder, clinicians should recognize that the observational design of included studies introduces substantial confounding limitations—maternal cannabis use frequently co-occurs with other substance use, psychiatric conditions, socioeconomic factors, and prenatal care disparities that independently influence neurodevelopmental outcomes. The reported relative risk increase of 1.30 for ASD, though statistically significant across studies, represents a small absolute risk elevation that must be contextualized against baseline ASD prevalence and the heterogeneity of cannabis products, exposure timing, and dosing across studies. Additionally, reverse causality remains plausible; women with underlying psychiatric or neurological conditions that increase ASD risk in offspring may self-select into cannabis use for symptom management. Clinicians counseling pregnant patients should acknowledge this evidence while emphasizing that the precautionary principle reasonably supports recommending cannabis cessation during pregnancy, while recognizing that women with hyperemesis gravidar